Aeterna Zentaris Inc., of Charleston, S.C., reconfirmed its expectation that the pivotal, phase III trial for Zoptrex (zoptarelin doxorubicin) in women with advanced, recurrent endometrial cancer, is expected to be completed in the third quarter of 2016, with a planned new drug application for the candidate to follow in the first half of 2017.